Currently, most of the ongoing research focuses on the respiratory complication of SARS-CoV2 and little is known about the management of COVID-19 myocarditis. In our experience, high dosage glucocorticoids, inotropes, and V-A ECMO improved the clinical conditions of the patient.
Cardiogenic Shock in COVID 19 Fulminant Myocarditis Treated with V-A ECMO
A. D'Errico Ramirez;L. Giovannico;D. Parigino;V. Santeramo;G. Fischetti;S. Grasso;A. Milano
2022-01-01
Abstract
Currently, most of the ongoing research focuses on the respiratory complication of SARS-CoV2 and little is known about the management of COVID-19 myocarditis. In our experience, high dosage glucocorticoids, inotropes, and V-A ECMO improved the clinical conditions of the patient.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
